DK2073837T3 - Rekombinant modificeret vaccinia-ankara-virus, der koder for et her-2-antigen, i kombination med en taxan til anvendelse til behandling af cancer - Google Patents

Rekombinant modificeret vaccinia-ankara-virus, der koder for et her-2-antigen, i kombination med en taxan til anvendelse til behandling af cancer

Info

Publication number
DK2073837T3
DK2073837T3 DK07839307.1T DK07839307T DK2073837T3 DK 2073837 T3 DK2073837 T3 DK 2073837T3 DK 07839307 T DK07839307 T DK 07839307T DK 2073837 T3 DK2073837 T3 DK 2073837T3
Authority
DK
Denmark
Prior art keywords
taxan
antigen
combination
cancer treatment
modified vaccinia
Prior art date
Application number
DK07839307.1T
Other languages
Danish (da)
English (en)
Inventor
Alain Delcayre
Reiner Laus
Stefanie Mandl
Original Assignee
Bavarian Nordic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic Inc filed Critical Bavarian Nordic Inc
Application granted granted Critical
Publication of DK2073837T3 publication Critical patent/DK2073837T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK07839307.1T 2006-10-06 2007-10-05 Rekombinant modificeret vaccinia-ankara-virus, der koder for et her-2-antigen, i kombination med en taxan til anvendelse til behandling af cancer DK2073837T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85003106P 2006-10-06 2006-10-06
PCT/US2007/021436 WO2008045346A2 (en) 2006-10-06 2007-10-05 Recombinant modified vaccinia ankara encoding a her-2 antigen for use in treating cancer

Publications (1)

Publication Number Publication Date
DK2073837T3 true DK2073837T3 (da) 2014-09-29

Family

ID=39283388

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13154196.3T DK2596801T3 (en) 2006-10-06 2007-10-05 RECOMBINANT MODIFIED VACCINIA ANKARA VIRUS CODING A HER-2 ANTIGEN FOR USING CANCER TREATMENT
DK07839307.1T DK2073837T3 (da) 2006-10-06 2007-10-05 Rekombinant modificeret vaccinia-ankara-virus, der koder for et her-2-antigen, i kombination med en taxan til anvendelse til behandling af cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK13154196.3T DK2596801T3 (en) 2006-10-06 2007-10-05 RECOMBINANT MODIFIED VACCINIA ANKARA VIRUS CODING A HER-2 ANTIGEN FOR USING CANCER TREATMENT

Country Status (11)

Country Link
US (2) US7807146B2 (enExample)
EP (2) EP2073837B1 (enExample)
JP (2) JP5964540B2 (enExample)
AU (1) AU2007307080B2 (enExample)
CA (1) CA2665068C (enExample)
DK (2) DK2596801T3 (enExample)
ES (1) ES2500465T3 (enExample)
IL (1) IL197633A (enExample)
NZ (2) NZ575388A (enExample)
PT (1) PT2073837E (enExample)
WO (1) WO2008045346A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2421151C (en) * 2000-11-23 2013-07-02 Bavarian Nordic A/S Modified vaccinia ankara virus variant
DK2596801T3 (en) * 2006-10-06 2018-08-13 Bavarian Nordic As RECOMBINANT MODIFIED VACCINIA ANKARA VIRUS CODING A HER-2 ANTIGEN FOR USING CANCER TREATMENT
US20110206736A1 (en) * 2008-09-23 2011-08-25 Thomas Jefferson University Cancer Vaccines Against Mucosal Antigens and Methods of Making and Using the Same
WO2012059376A1 (en) * 2010-11-02 2012-05-10 Telefonaktiebolaget L M Ericsson (Publ) Methods and devices for media description delivery
US9463238B2 (en) 2011-12-09 2016-10-11 Bavarian Nordic A/S Recombinant poxvirus vector comprising tetanus toxin fragment C
DK2788021T3 (en) 2011-12-09 2017-04-10 Bavarian Nordic As POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
AU2013331328B2 (en) * 2012-10-19 2018-05-31 Bavarian Nordic A/S Methods and compositions for the treatment of cancer
EP2777711A1 (en) * 2013-03-11 2014-09-17 Icon Genetics GmbH Her2/Neu cancer vaccine
WO2015000936A1 (en) 2013-07-03 2015-01-08 Koninklijke Kpn N.V. Streaming of segmented content
ES2693213T3 (es) 2013-10-23 2018-12-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epítopos agonistas de HLA-A24 de oncoproteína MUC1-C y composiciones y métodos de uso
CN115300622A (zh) 2015-02-25 2022-11-08 纪念斯隆-凯特琳癌症中心 使用灭活的修饰的痘苗病毒安卡拉作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂组合
CN107847534B (zh) 2015-04-17 2022-10-04 纪念斯隆凯特琳癌症中心 Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
WO2017147553A2 (en) 2016-02-25 2017-08-31 Memorial Sloan-Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
SG11201807022XA (en) 2016-02-25 2018-09-27 Memorial Sloan Kettering Cancer Center Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
US11242509B2 (en) 2017-05-12 2022-02-08 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
CN110603058A (zh) 2017-05-15 2019-12-20 扬森疫苗与预防公司 含有病毒的稳定组合物
EP3624845A1 (en) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3706768A4 (en) * 2017-11-06 2021-08-25 Memorial Sloan Kettering Cancer Center USE OF THE HEAT-INACTIVATED VACCINE VIRUS AS A VACCINE IMMUNE ADJUDENT
MX2021003013A (es) 2018-09-15 2021-08-11 Memorial Sloan Kettering Cancer Center Poxvirus recombinantes para inmunoterapia contra cáncer.
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
AU2020385683A1 (en) 2019-11-18 2022-06-30 Janssen Biotech, Inc. Vaccines based on mutant CALR and JAK2 and their uses
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
ATE415173T1 (de) 1993-09-14 2008-12-15 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
US6326356B1 (en) * 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
DE19729279A1 (de) 1997-07-09 1999-01-14 Peter Hildebrandt Urologisches Implantat, insbesondere Gefäßwandstütze für den Urinaltrakt
HK1039749B (zh) * 1998-10-05 2007-10-05 法麦克萨有限公司 Ctl表位和t辅助淋巴细胞表位在免疫接种中的应用
DE10042598A1 (de) * 2000-08-30 2002-03-28 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS
CA2421151C (en) 2000-11-23 2013-07-02 Bavarian Nordic A/S Modified vaccinia ankara virus variant
WO2003026581A2 (en) * 2001-09-26 2003-04-03 Intermune, Inc. Pharmaceutical compositions and methods for treating cancer
ATE418333T1 (de) * 2002-11-06 2009-01-15 Cyclacel Ltd Kombination aus docetaxel und einem cdk-hemmer
AU2003297155B2 (en) * 2002-12-16 2010-03-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant vaccine viruses expressing IL-15 and methods of using the same
CN1511549A (zh) * 2002-12-27 2004-07-14 张小丽 含有黄芩的抗肿瘤、抗炎症及肿瘤预防药物的组合物
ITMI20030317A1 (it) * 2003-02-21 2004-08-22 Pharmacia Italia Spa Terapia combinata comprendente un derivato dell'indolopirrolocarbazolo ed un altro agente antitumorale.
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
WO2004103301A2 (en) * 2003-05-16 2004-12-02 Hybridon, Inc. Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
US7763452B2 (en) 2003-06-25 2010-07-27 Bn Immunotherapeutics, Inc. Purification of HER-2 variants
EP1641819B1 (en) * 2003-06-25 2009-04-22 BN ImmunoTherapeutics, Inc. Purification of her-2 variants
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
DK1855720T4 (da) 2005-02-23 2023-07-24 Bavarian Nordic As Anvendelse af et modificeret poxvirus til hurtig induktion af immunitet mod et poxvirus eller andre smitstoffer
DK2596801T3 (en) 2006-10-06 2018-08-13 Bavarian Nordic As RECOMBINANT MODIFIED VACCINIA ANKARA VIRUS CODING A HER-2 ANTIGEN FOR USING CANCER TREATMENT

Also Published As

Publication number Publication date
US8313740B2 (en) 2012-11-20
ES2500465T3 (es) 2014-09-30
WO2008045346A3 (en) 2009-06-04
EP2073837A2 (en) 2009-07-01
AU2007307080B2 (en) 2014-01-09
CA2665068C (en) 2016-01-05
US7807146B2 (en) 2010-10-05
WO2008045346A2 (en) 2008-04-17
JP6124822B2 (ja) 2017-05-10
NZ575388A (en) 2012-03-30
PT2073837E (pt) 2014-09-22
EP2073837B1 (en) 2014-06-25
JP2014129416A (ja) 2014-07-10
IL197633A (en) 2017-03-30
EP2596801A1 (en) 2013-05-29
NZ597998A (en) 2013-08-30
CA2665068A1 (en) 2008-04-17
US20110008294A1 (en) 2011-01-13
DK2596801T3 (en) 2018-08-13
AU2007307080A1 (en) 2008-04-17
US20080213302A1 (en) 2008-09-04
JP2010505850A (ja) 2010-02-25
EP2596801B1 (en) 2018-05-02
JP5964540B2 (ja) 2016-08-03
IL197633A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
DK2073837T3 (da) Rekombinant modificeret vaccinia-ankara-virus, der koder for et her-2-antigen, i kombination med en taxan til anvendelse til behandling af cancer
DK1827441T3 (da) Kombinationer til behandling af sygdomme, som involverer celleproliferation
DK2224822T3 (da) Polypeptider med acetylxylanesterase-aktivitet og polynukleotider, der koder for disse
ATE513831T1 (de) Pyridinä3,4-büpyrazinone
DK1957106T4 (da) Antagonist-antistoffer, der er rettet mod calcitonin-gen-relateret peptid og fremgangsmåder til anvendelse af disse
SE0400425L (sv) Förfarande för behörighetsgivande
DK1817340T3 (da) Fc-varianter med ændret binding til fcrn
DK1751181T3 (da) BINDINGSDELE, DER ER BASERET PÅ HAJ IgNAR-DOMÆNER
DE502007005517D1 (de) Härtbare, dentale Massen
DK2209375T3 (da) Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf
DK2032701T3 (da) Polynukleotider og polypeptider, der er inddraget i cancer
DK2179040T3 (da) Sammensætninger og fremgangsmåder til behandling af tumorer, fibrose og alveolæreproteinose
DE602006021707D1 (de) Epoxidharzzusammensetzung, daraus erhaltenes gehäres phenolharz und neues epoxidharz
DK2139483T3 (da) Kombinationsterapier, der omfatter en quinoxalin-inhibitor af PI3K-alfa, til anvendelse til behandling af cancer
DE602004027424D1 (de) Operationsverwaltungsprogramm, operationsverwaltun
GB0613360D0 (en) Bar code authentication
DE602005021328D1 (de) Flashspunvlies mit verbesserter atmungsaktivität
DK2350554T3 (da) Fremgangsmåde til fremstilling af en granatsikker og skudsikker struktur, og granatsikker og skudsikker struktur
FR2918830B1 (fr) Verification de code mac sans revelation.
DE502005007723D1 (de) 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactone,
DE602005007364D1 (de) Peptidcyclisierung
GB2434663B (en) One-time password authentication
ATE519085T1 (de) EINRICHTUNG ZUM DROSSELN VON HEIßEN, STAUBBELASTETEN GASSTRÖMEN
ES1056663Y (es) Abrazadera.
DK1931304T3 (da) Hidtil ukendt anvendelse til en sammensætning, der omfatter chlorprocain-HCl, en hidtil ukendt sammensætning, der omfatter chlorprocain-HCl og en fremgangsmåde til fremstilling deraf